

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the present application.

IN THE CLAIMS:

1. (Withdrawn) A preparation for continuous intravenous administration containing hepatocyte growth factor (HGF) as an active ingredient.
2. (Withdrawn) The preparation for continuous intravenous administration of claim 1, wherein the preparation is used in treatment or prevention of renal disease.
3. (Withdrawn) The preparation for continuous intravenous administration of claim 2, wherein the renal disease is acute renal failure or chronic renal failure.

4. (Withdrawn) The preparation for continuous intravenous administration of claim 1, wherein the preparation is used in treatment or prevention of occlusive lesion of blood vessel.

5. (Withdrawn) The preparation for continuous intravenous administration of claim 4, wherein the occlusive lesion of blood vessel includes lower limb ischemia, acute arterial occlusion, chronic arterial occlusion, arteriosclerosis obliterans, arterial embolism, arterial thrombosis, Buerger's disease, venous occlusion, venous thrombosis, thrombotic phlebitis, angiodyplasia, vascular damage, coronary occlusion, coronary stenosis, pulmonary embolism, and arterial occlusion of organs.

6. (Currently Amended) A method for treating or preventing renal failure renal disease, which comprises administering administering an effective amount of hepatocyte growth factor (HGF) HGF by continuous intravenous administration to a patient suffering from renal failure,
thereby treating renal failure in said patient.

7. (Currently Amended) A method for treating ~~or preventing~~ occlusive lesion of blood vessel, which comprises administering administering an effective amount of hepatocyte growth factor (HGF) HGF by continuous intravenous administration to a patient suffering from occlusive lesion of blood vessel, thereby treating occlusive lesion of blood vessel in said patient.